Health - The Post Chronicle (Free subscription) | 11/24/2008
Roche Holding AG, the world's largest maker of cancer drugs, said on Monday that Avastin met its primary endpoint in a Phase III breast cancer trial....
Reuters (Free subscription) | 11/09/2008
ZURICH (Reuters) - Roche Holding AG is sticking by its $43.7 billion offer to buy out the rest of Genentech Inc it does not already own, its pharmaceuticals chief said in an interview published on Sunday.
Law Blog - WSJ.com (Free subscription) | 11/10/2008
NOVEMBER 10, 2008 Roche Says Tarceva Data Promising A NEWS ROUNDUP more in »Roche Holding AG said Friday its drug Tarceva was shown to extend the lives of patients with lung cancer without their tumor growing when given immediately after chemotherapy.... Share: Yahoo! Buzz facebook MySpace LinkedIn Digg del.icio.us NewsVine StumbleUpon Mixx Back To Email Newsletters and AlertsThe...
Market Watch (Free subscription) | 11/07/2008
LONDON (MarketWatch) -- Roche Holdings said a study of Tarceva showed the drug met its primary endpoint of delaying lung cancer progression when given following treatment with chemotherapy. Roche said it will discuss with regulatory agencies the data and plans for filing of a new indication and will continue a development program with OSI Pharmaceuticals and Genentech . Market...
Reuters (Free subscription) | 10/21/2008
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG confirmed its commitment to a $43.7 billion bid for Genentech Inc as it reported a 2 percent fall in nine-month sales to 33.3 billion Swiss francs ($29.26 billion).
Market Watch (Free subscription) | 10/21/2008
LONDON (MarketWatch) -- Swiss pharmaceutical company Roche Holdings AG on Tuesday posted a 1.6% increase in third-quarter sales, helped by strong demand for its Avastin and Herceptin cancer drugs, and confirmed its outlook for the year.
Boston Globe (Free subscription) | 10/21/2008
Swiss drugmaker Roche Holding AG confirmed its commitment to a $43.7 billion bid for Genentech Inc as it reported a 2 percent fall in nine-month sales to 33.3 billion Swiss francs ($29.26 billion).
Red Orbit (Free subscription) | 11/21/2008
... 34 percent of chemotherapy patients.Two other lung cancer drugs, Tarceva and Avastin, made by Roche Holding AG, are already on the market in the United Kingdom, and Tarceva works similarly to Iressa, which has only been approved in the U.S. so far. "In the patients that respond, it is very dramatic," said Seckl, who has seen patients live years on the drug. He did not work with AstraZeneca...
MSNBC.com (Free subscription) | 11/21/2008
... on a limited compassionate use basis.Two other lung cancer drugs, Tarceva and Avastin, made by Roche Holding AG, are already on the market in the United Kingdom, and Tarceva works similarly to Iressa.In the study, paid for by AstraZeneca, researchers studied 1,433 advanced lung cancer patients in 24 countries, who had already gone through chemotherapy. Roughly half were given Iressa,...
Seattle Post-Intelligencer (Free subscription) | 11/21/2008
... on a limited compassionate use basis.Two other lung cancer drugs, Tarceva and Avastin, made by Roche Holding AG, are already on the market in the United Kingdom, and Tarceva works similarly to Iressa.In the study, paid for by AstraZeneca, researchers studied 1,433 advanced lung cancer patients in 24 countries, who had already gone through chemotherapy. Roughly half were given Iressa,...
Best Practice Exchange (Free subscription) | 11/09/2008
Image by Getty Images via Daylife Genentech Roche Talks Continue One of the 2008 Fortune Top 100 Great Places to Work has been the subject of acquisition rumors since July. Genentech is being eyed by Roche Holding AG . Roche already holds a large portion of outstanding Genentech stock and would like to acquire the rest. According to Reuters , Roche is sticking by...
Science - The Post Chronicle (Free subscription) | 11/11/2008
... the company would be open to licensing its test to one of the larger diagnostic companies, such as Roche Holding AG. He also said Brahms was likely to become a public company in the foreseeable future.The Brahms test uses a biomarker it discovered called MR-proADM (Mid-Regional pro-Adrenomedullin). The 1,641-patient study called Bach compared its accuracy in predicting patients likely...
CEOWORLD Magazine (Free subscription) | 11/05/2008
Swiss dental implant maker Nobel Biocare Holding AG said on Wednesday talk that chief executive Domenico Scala was to leave the company was unfounded. “There are no indications that the chief executive will change,” a Nobel Biocare spokesman told Reuters. Shares of the world’s largest maker of dental implants rose some 5 percent, outperforming an overall weaker [...]
Business Wire (Free subscription) | 11/06/2008
... Inc. - - Krenitsky Pharmaceuticals Inc. - - Pharmaxon - - Nyxis Neurotherapies, Inc. - - Roche Holdings Ltd - - Proteome Systems Limited - - Targacept Inc - - Suven Life Sciences Limited - - Xytis, Inc. - - Vasogen Inc
Business Week (Free subscription) | 10/31/2008
... down 33%, represents the value of blue-chip Swiss companies such as Nestlé (), Novartis (), and Roche Holding. It has been only about 60% as volatile as the U.S. market over the past three years and should do better than the U.S. in a recession, Delfeld says. Other investors looking for a gold alternative have ventured into silver. The lower-priced precious metal isn't included in...
